Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
Appointed director
Sage Therapeutics, Inc. (SAGE) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/07/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/07/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress"
07/10/2023 SC 13G/A WELLINGTON MANAGEMENT GROUP LLP reports a 10.6% stake in Sage Therapeutics, Inc.
06/16/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Amended and Restated Bylaws of Sage Therapeutics, Inc"
06/07/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/02/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/02/2023 8-K Quarterly results
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/16/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
02/09/2023 SC 13G/A FMR LLC reports a 11% stake in SAGE THERAPEUTICS INC
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 8.2% stake in Sage Therapeutics Inc.
02/06/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/06/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression"
02/03/2023 SC 13G BlackRock Inc. reports a 8.3% stake in SAGE THERAPEUTICS INC
01/09/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Corporate Presentation dated January 2023",
"Sage Therapeutics to Provide Update on 2023 Key Initiatives at 41st Annual J.P. Morgan Healthcare Conference"
12/06/2022 8-K Quarterly results
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/08/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress"
08/02/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/02/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/02/2022 8-K Quarterly results
Docs: "Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeline and Business Progress"
07/14/2022 8-K Quarterly results
07/11/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
06/21/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
06/01/2022 8-K Quarterly results
05/03/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/03/2022 8-K Quarterly results
04/28/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
02/24/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy